Detrimental clinical interaction between ritonavir-boosted protease inhibitors and vinblastine in HIV-infected patients with Hodgkin's lymphoma.

Abstract

In order to analyze the clinical relevance of the pharmacokinetic interactions between vinblastine and antiretrovirals described in literature, we evaluated all HIV-infected patients with Hodgkin's lymphoma treated with vinblastine-containing regimens and combination antiretroviral therapy, in a single clinical center. The use of protease inhibitors was independently associated with WHO grade III-IV neutropenia. Moreover, an inverse correlation between dosage of ritonavir and mean nadir neutrophil count was found. The concomitant administration of vinblastine-containing chemotherapy regimens with protease inhibitors can lead to higher levels of neutropenia than those of different classes of drugs such as nonnucleoside reverse transcriptase inhibitors or integrase inhibitors.

• Authors: Antonella Cingolani, Lorenza Torti, Carmela Pinnetti, Katleen de Gaetano Donati, Rita Murri, Evelina Tacconelli, Luigi Maria Larocca, Luciana Teofili
• Journal: AIDS (London, England) (AIDS) Vol. 24 Issue 15 Pg. 2408-12 (Sep 24 2010) ISSN: 1473-5571 [Electronic] England
• PMID: 20671541 (Publication Type: Journal Article)

Chemical References

• HIV Protease Inhibitors
• Vinblastine
• Ritonavir

Topics

• Adult
• Aged
• Drug Interactions
• Female
• HIV Infections (drug therapy, immunology)
• HIV Protease Inhibitors (administration & dosage, pharmacokinetics)
• Hodgkin Disease (drug therapy, immunology)
• Humans
• Male
• Middle Aged
• Ritonavir (administration & dosage, pharmacokinetics)
• Vinblastine (administration & dosage, pharmacokinetics)